摘要
目的探究并分析经尿道前列腺汽化术治疗高危前列腺增生症(BPH)的临床效果和安全性。方法选取2008年9月至2009年9月东莞市企石医院收治的高危BPH患者110例作为临床研究对象。按入院顺序将所有患者随机分成前列腺切除术组和前列腺汽化术组,各55例。前列腺切除术组患者采用经尿道前列腺电切术治疗,前列腺汽化术组患者采用经尿道前列腺汽化术治疗。测量记录两组患者手术中的平均出血量、手术时间、切除腺组织重量和两组患者术前及术后2个月的最大尿流率、平均尿流率和剩余尿量,并对所得数据进行分析。结果前列腺切除术组患者手术时间和平均出血量高于前列腺切除术组(t=4.387,P<0.05),前列腺汽化术组患者术后2个月的最大尿流率、平均尿流率较前列腺切除术组显著升高(t=4.52,P<0.05),剩余尿量较前列腺切除术组显著减少(t=5.013,P<0.05)。结论采用经尿道前列腺汽化术对高危BPH患者术中的平均出血量、手术时间、术后2个月的最大尿流率、平均尿流率和剩余尿量,全面优于常规经尿道前列腺电切术。
Objective To explore and analyze clinical effects and safety of using transurethral prostate electrovaporization to treat high-risk benign prostate hyperplasia.Methods A total of 110 cases of those high-risk benign prostate hyperplasia patient admitted to Donggnan City Qishi Hospital from Sep.2008 to Sep.2009 were included as clinical study objects.They were randomly divided into group A and group B,55 cases in each group,group A was prostatectomy group and group B was prostate electrovaporization group.Average bleeding volum,operation time,maximum urine flow rate,average flow rate and residual urine volume before and after two months of the treatment of the two groups were measured,recorded,and analyzed.Results Group A's average operation time and bleeding amount were higher than group B 's (t =4.387,P 〈 0.05),compared with the situation before treatment,group B's maximum flow rate and average flow rate improved significantly(t =4.52,P 〈 0.05),and their residual urine volume decreased significantly,with statistically significant difference(t =5.013,P 〈 0.05).Conclusion The clinical effect of transurethral prostate vaporization to treat high-risk benign prostate hyperplasia patients is all better than conventional prostatectomy in aspects of average bleeding,operation time,maximum urine flow rote 2 months after surgery,average urine flow rate and urine residual amount.fewer complications,higher security and better clinical curative effect.
出处
《医学综述》
2014年第6期1134-1135,共2页
Medical Recapitulate
关键词
经尿道前列腺汽化术
高危
前列腺增生
安全性
Transurethral vaporization of prostate
High-risk
Benign prostatic hyperplasia
Safety